ReviewNanomedicine (London, England)2025
Near-infrared II nanomaterials for hypoxic TME diagnosis and therapy.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tumor Microenvironment-Responsive Polymeric Nanocarriers for the Treatment of Triple-Negative Breast Cancer.Pharmaceutics · 2026Review
- "Ferroptosis-immune" cycle: Research progress of tumor microenvironment responsive nanomaterials in the treatment of pancreatic cancer.iScience · 2026Review
- Progress in targeting tumor-associated macrophages in cancer immunotherapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxic tumor microenvironments (TME) drive cancer aggression and therapy resistance, necessitating precise diagnostic and therapeutic strategies. Near-Infrared II (NIR-II) nanomaterials have emerged as transformative tools for addressing hypoxic TME challenges, leveraging deeper tissue penetration, minimal scattering, and reduced autofluorescence. This review systematically summarizes the recent advancements in NIR-II nanomaterials, focusing on their applications in imaging and therapy for hypoxic tumors. NIR-II-based imaging techniques, including fluorescence, photoacoustic, and multimodal imaging, provide high sensitivity and resolution for detecting hypoxic regions, aiding in early diagnosis and personalized treatment planning. In therapeutic applications, NIR-II materials enhance the efficacy of photothermal therapy, photodynamic therapy, and photo-Fenton therapy, all of which overcome the limitations of traditional therapies in hypoxic areas. The combination of NIR-II materials with other treatment modalities holds promise for more effective cancer treatments. This review also discusses the challenges in the current research landscape, including the preparation, scalability, and clinical translation of NIR-II materials. It highlights the need for continued innovation to optimize these materials for broader clinical applications. Overall, NIR-II nanomaterials represent a significant step forward in addressing the challenges posed by hypoxic tumors, with the potential to revolutionize cancer diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.